- 产品描述
牛巴贝西虫免疫荧光试剂盒
babesia bovis IFA Kit
广州健仑生物科技有限公司
主要用途:用于检测牛血清中的牛巴贝西虫IgG/IgM抗体
产品规格:12 孔/张,10 张/盒
主要产品包括:包柔氏螺旋体菌、布鲁氏菌、贝纳特氏立克次体、土伦杆菌、钩端螺旋体、新型立克次体、恙虫病、立克次体、果氏巴贝西虫、马焦虫、牛焦虫、利什曼虫、新包虫、弓形虫、猫流感病毒、猫冠状病毒、猫疱疹病毒、犬瘟病毒、犬细小病毒等病原微生物的 IFA、MIF、ELISA试剂。
牛巴贝西虫免疫荧光试剂盒
我司还提供其它进口或国产试剂盒:登革热、疟疾、西尼罗河、立克次体、无形体、蜱虫、恙虫、利什曼原虫、RK39、汉坦病毒、深林脑炎、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、化妆品检测、食品安全检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。
欢迎咨询
欢迎咨询2042552662
JL-FL54 | 牛双芽巴贝西虫免疫荧光玻片 | babesia bigemina IFA Substrate slide |
JL-FL55 | 牛双芽巴贝西虫免疫荧光试剂盒 | babesia bigemina IFA Kit |
JL-FL56 | 牛巴贝西虫免疫荧光玻片 | babesia bovis IFA Substrate slide |
JL-FL57 | babesia bovis IFA Kit | |
JL-FL58 | 驽巴贝西虫免疫荧光玻片 | babesia caballi IFA Substrate slide |
JL-FL59 | 驽巴贝西虫免疫荧光试剂盒 | babesia caballi IFA Kit |
JL-FL60 | 马泰勒虫免疫荧光玻片 | theileria equi IFA Substrate slide |
JL-FL61 | 马泰勒虫免疫荧光试剂盒 | theileria equi IFA Kit |
JL-FL62 | 利什曼虫IgG免疫荧光试剂盒 | Leishmania IgG IFA Kit |
JL-FL63 | 新孢子虫IgG免疫荧光试剂盒(检测狗) | Neospora caninum IgG IFA Kit |
JL-FL64 | 新孢子虫IgG免疫荧光试剂盒(检测马) | Neospora caninum IgG IFA Kit |
JL-FL65 | 猫杯状病毒IgG免疫荧光玻片 | Feline Calicivirus IgG IFA Substrate slide |
JL-FL66 | 猫冠状病毒IgG免疫荧光玻片 | Feline Coronavirus IgG IFA Substrate slide |
JL-FL67 | 猫疱疹病毒IgG免疫荧光玻片 | Feline Herpesvirus IgG IFA Substrate slide |
JL-FL68 | 犬瘟病毒IgG免疫荧光玻片 | Canine Distemper IgG IFA Substrate slide |
JL-FL69 | 犬细小病毒IgG免疫荧光玻片 | Canine Parvovirus IgG IFA Substrate slide |
二维码扫一扫
【公司名称】 广州健仑生物科技有限公司
【】 杨永汉
【】
【腾讯 】 2042552662
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-3室
【企业文化】
Benz认为这一研究将能被用于临床试验设计,尤其是希望能通过肿瘤基因组重分类,寻找新的治疗方法的患者,“虽然需要后续的研究来验证,并完善这一新提出的癌症分类系统,但是这项研究zui终将能为个性化癌症医疗时代的到来,奠定基础生物学基础。”
尽管目前正在开发各种化合物对抗癌症,但它们都具有严重的副作用。此外,肿瘤能够对这些化合物产生耐药。
为了抵消上述两个缺点,科学家们设计了一种基于肽的新疗法,利用黄蜂毒液中的多肽,作为预防抗原抗体癌的潜在新方法。
这种肽具有在细胞质膜形成孔的能力,并穿透进入癌细胞,或诱导癌细胞坏死或触发凋亡,zui后导致癌细胞死亡。
然而,这种强大的“自然武器”目前还不能用于治疗,这是由于它的高毒性和缺乏细胞特异性,它不仅会损害肿瘤细胞,也将影响患者的健康细胞。因此,研究人员设计一种手段,以一个特定的和可控制的方式输送肽到肿瘤,并使其在肿瘤细胞中堆积。
该系统由装载两个“组件”的载体聚合物组成:能绑定到肿瘤细胞受体的肽和黄蜂毒液的毒性肽。体外实验表明,黄蜂毒液的毒性肽被充分地递送分布在肿瘤细胞内,并导致其死亡,而正常细胞如红细胞不受影响。
Benz believes the study will be used in clinical trial design, especially in patients wishing to reclassify the tumor genome to find new treatments, "although follow-up studies are needed to validate and refine the newly proposed cancer classification System, but the research will ultimay lay the foundations of basic biology for the advent of the personalized cancer care era. "
Although various compounds are currently being developed to combat cancer, they all have serious side effects. In addition, tumors can become resistant to these compounds.
In order to counteract the above two drawbacks, scientists have designed a new peptide-based therapy that uses the polypeptide in wasp venom as a potential new method of preventing antigen-antibody cancer.
This peptide has the ability to form pores in the plasma membrane and penetrates into cancer cells, induces necrosis or triggers apoptosis in cancer cells, and ultimay leads to the death of cancer cells.
However, this powerful "natural weapon" is currently not available for treatment due to its high toxicity and lack of cell specificity, which not only damages tumor cells but also affects healthy cells in patients. Therefore, the researchers devised a means to deliver the peptide to the tumor in a specific and controlled manner and allow it to accumulate in the tumor cells.
The system consists of a carrier polymer loaded with two "assemblies": a toxic peptide that binds to a tumor cell receptor peptide and wasps venom. In vitro experiments showed that the virulent peptide of the wasp venom is sufficiently delivered to distribute within the tumor cells and cause its death, whereas normal cells such as red blood cells are unaffected.